Medtide Inc
03880
Company Profile
Business description
Medtide Inc offers full-cycle services ranging from early-stage discovery, preclinical research and clinical development to commercial-stage production. It mainly provide (i) CRO services, namely peptide NCE discovery synthesis; and (ii) CDMO services, namely peptide CMC development and commercial manufacturing. Its services focus on providing customers with APIs rather than drug products.
Contact
No. 69, 12 Street
Qiantang District
Zhejiang
Hangzhou
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
520
Stocks News & Analysis
stocks
Alibaba fair value increases by 49%
Stronger-than-expected AI demand internationally and domestically.
stocks
A 5-Star US stock to buy with a near-5% yield
Undervalued by 23%, this cheap dividend stock is a top pick in its sector.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,150.70 | 47.60 | 0.52% |
| CAC 40 | 7,870.68 | 75.26 | 0.97% |
| DAX 40 | 23,739.47 | 204.64 | 0.87% |
| Dow JONES (US) | 46,247.29 | 299.97 | 0.65% |
| FTSE 100 | 9,284.83 | 70.85 | 0.77% |
| HKSE | 26,393.92 | 265.72 | 1.02% |
| NASDAQ | 22,484.07 | 99.37 | 0.44% |
| Nikkei 225 | 44,926.34 | 428.65 | -0.95% |
| NZX 50 Index | 13,238.55 | 126.82 | 0.97% |
| S&P 500 | 6,643.70 | 38.98 | 0.59% |
| S&P/ASX 200 | 8,864.30 | 53.60 | 0.61% |
| SSE Composite Index | 3,814.83 | 13.28 | -0.35% |